Latest Content

Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

Shane Lloyd, MD, MHS, and Christos Vaklavas, MD, were selected as new Huntsman Cancer Institute Translational Scholars for their leadership in bridging laboratory discoveries with clinical innovation.

Hagop Kantarjian, MD, discusses the arsenal of TKIs approved for chronic myeloid leukemia and how to navigate them regarding treatment selection.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

The FDA has approved sacituzumab govitecan monotherapy and in combination with pembrolizumab in frontline TNBC.

Izalontamab brengitecan was approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

The FDA has approved palbociclib plus trastuzumab, with/without pertuzumab, and ET as maintenance in HR+, HER2+ metastatic breast cancer.

The European Commission approved perioperative pembrolizumab plus enfortumab vedotin for patients with cisplatin-ineligible resectable MIBC.

Mayo Clinic scientists have revealed the molecular structures of PKCβ, a key protein linked to cancer and neurological diseases.

An off-the-shelf BCMA-directed CAR T-cell therapy generated a 100% overall response rate and universal MRD negativity in heavily pretreated myeloma.

Christian Grommes, MD, and Ashley Sumrall, MD, FACP, FASCO, discuss the phase 3 IGNITE trial of tirabrutinib in PCNSL.

The NCCN has included tumor-informed multiplex PCR ctDNA-MRD testing in the treatment approach for patients with MIBC.

The European Commission approved first-line sacituzumab govitecan as monotherapy for unresectable/metastatic TNBC not eligible for PD-(L)1 inhibition.